Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18-64 years: A systematic review and Meta-analysis.
10.3760/cma.j.issn.0254-6450.2018.12.019
- Author:
Z Y MENG
1
,
2
;
J Y ZHANG
1
,
2
;
Z G ZHANG
1
,
2
;
D LUO
1
,
2
;
X M YANG
3
Author Information
1. National Engineering Technology Research Center of Combination Vaccines, Wuhan 430207, China
2. Wuhan Institute of Biological Products, Wuhan 430207, China.
3. National Engineering Technology Research Center of Combination Vaccines, Wuhan 430207, China.
- Publication Type:Systematic Review
- Keywords:
Immunogenicity;
Influenza vaccine;
Meta-analysis;
Quadrivalent influenza vaccine;
Random control trial;
Vaccines, inactivated
- MeSH:
Adolescent;
Adult;
Antibodies, Viral/blood*;
Drug-Related Side Effects and Adverse Reactions;
Hemagglutination Inhibition Tests;
Humans;
Influenza A virus/immunology*;
Influenza B virus/immunology*;
Influenza Vaccines/immunology*;
Influenza, Human/prevention & control*;
Middle Aged;
Vaccines, Inactivated/immunology*;
Young Adult
- From:
Chinese Journal of Epidemiology
2018;39(12):1636-1641
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the immunogenicity of inactivated quadrivalent influenza vaccine (QIV) in adults aged 18-64 years, through a Meta-analysis. Methods: Literature was retrieved by searching the Medline, Cochrane Library, Science Direct in the past decade. All the studies were under random control trial (RCT) and including data related to immunogenicity which involving sero-protection rate (SPR) and sero-conversion rate (SCR) of the QIV, versus inactivated trivalent influenza vaccine (TIV) in the population aged 18 to 64. Revman 5.3 software was employed to manipulate the pooled date of the included literature. Result: A total of 8 studies for the SPR and SCR of the shared strains (two A lineage and one B lineage) were included. There appeared no significant differences in the response rates between the two vaccines. As for QIV versus TIV (B/Yamagata), the pooled RR of the SPR for B/Victoria was 1.28 (95%CI: 1.08-1.51, P<0.05), with the pooled RR of the SCR for B/Victoria as 1.94 (95%CI: 1.50-2.50, P<0.05). For QIV versus TIV (B/Victoria), the pooled RR of the SPR for B/Yamagata as 1.10 (95%CI: 1.02-1.18, P<0.05), and the pooled RR of SCR for B/Yamagata as 1.99 (95%CI: 1.34-2.97, P<0.05). Conclusion: In the population aged 18-64 years, inactivated QIV was equivalently immunogenic against the shared three strains included in the activated TIV while a superior immunogenic effect was noticed in the vaccine strain which did not include the inactivated QIV.
